Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arjo AB ( ($SE:ARJO.B) ) has provided an announcement.
Arjo AB’s 2026 Annual General Meeting in Malmö approved the 2025 financial statements and confirmed the company’s position with a global workforce of about 7,000 employees serving mobility-challenged patients and healthcare providers. The meeting underscored Arjo’s long-standing focus on safe and dignified patient care through a broad portfolio of medical technology solutions.
Shareholders approved a dividend of SEK 0.95 per share, granted discharge from liability to board members and former CEOs for 2025, and re-elected the existing board while adding Andréas Elgaard as a new director. Ernst & Young AB was reappointed as auditor, directors’ and committee fees were set, the remuneration report was endorsed, and the board received authorization to repurchase up to 10 percent of the company’s Class B shares, providing added flexibility in capital management.
The most recent analyst rating on ($SE:ARJO.B) stock is a Hold with a SEK32.00 price target. To see the full list of analyst forecasts on Arjo AB stock, see the SE:ARJO.B Stock Forecast page.
More about Arjo AB
Arjo AB is a global medical technology company focused on solutions that support mobility and safe care in healthcare environments. The company offers products such as patient handling equipment, medical beds, personal hygiene systems, disinfection solutions, diagnostic tools, and technologies for preventing pressure injuries and venous thromboembolism, serving patients and caregivers worldwide.
Average Trading Volume: 636,130
Technical Sentiment Signal: Sell
Current Market Cap: SEK7.33B
For a thorough assessment of ARJO.B stock, go to TipRanks’ Stock Analysis page.